CSIR's cancer drug enters clinical trials
Science & Technology
June 08, 2020
1 min read
A CSIR lab has received approval to conduct clinical trials of a new drug in pancreatic cancer patients.
Indian Institue of Integrative Medicine, Jammu is a drug research laboratory that works under the Council of Scientific & Industrial Research.
This approval has been given by the New Drugs Division of Central Drugs Standard Control Organization (CDSCO).
This drug has been created using the content from the leaves of Indian white cedar.
Globally, pancreatic cancer causes more than 2.5 lakh deaths annually.
This cancer is considered as one of the untreatable cancer types, because of its very late diagnosis.
Central Drugs Standard Control Organisation
Jammu and Kashmir
Council of Scientific & Industrial Research
Lieutenant Governor over-rules Delhi Government decision for hospital reservation
9 June: World Accreditation Day
NCL Pune develops indigenous nasopharyngeal swabs
June 06, 2020
Medical devices to be regulated under Drugs and Cosmetics Act
February 12, 2020
Girish Chandra Murmu becomes first Lieutenant Governor of J&K
November 01, 2019
IIT Madras creates high-performance Magnesium alloy
May 28, 2020
ICMR gives approval to plasma therapy trials for COVID-19 treatment
April 11, 2020
Biofortified carrot variety developed by Indian farmer scientist
April 08, 2020
© 2021, All Rights Reserved.